Insmed Incorporated Share Price

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
63.92 USD +3.72% Intraday chart for Insmed Incorporated +12.44% +106.26%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 353M 27.85B Sales 2025 * 509M 40.11B Capitalization 9.94B 784B
Net income 2024 * -707M -55.75B Net income 2025 * -666M -52.52B EV / Sales 2024 * 29.5 x
Net Debt 2024 * 493M 38.87B Net Debt 2025 * 597M 47.08B EV / Sales 2025 * 20.7 x
P/E ratio 2024 *
-14.2 x
P/E ratio 2025 *
-15.9 x
Employees 912
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.72%
1 week+11.81%
Current month+16.11%
1 month+147.46%
3 months+129.60%
6 months+122.64%
Current year+106.26%
More quotes
1 week
56.03
Extreme 56.03
65.00
1 month
21.92
Extreme 21.92
65.00
Current year
21.92
Extreme 21.92
65.00
1 year
19.01
Extreme 19.01
65.00
3 years
16.04
Extreme 16.04
65.00
5 years
12.09
Extreme 12.09
65.00
10 years
9.02
Extreme 9.02
65.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 09/09/12
Director of Finance/CFO 43 30/01/20
Chief Tech/Sci/R&D Officer 60 18/12/19
Members of the board TitleAgeSince
Director/Board Member 60 31/03/20
Director/Board Member 65 01/08/12
Director/Board Member 73 30/04/01
More insiders
Date Price Change Volume
14/06/24 63.92 +3.72% 3,300,016
13/06/24 61.63 -0.03% 4,327,450
12/06/24 61.65 -0.36% 3,660,886
11/06/24 61.87 +3.29% 4,158,865
10/06/24 59.9 +5.36% 4,578,805

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
63.92 USD
Average target price
68.62 USD
Spread / Average Target
+7.36%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW